Biora Therapeutics Says Company Did Not Regain Compliance With Nasdaq's MVLS Rule By June 10, 2024
Portfolio Pulse from Benzinga Newsdesk
Biora Therapeutics announced that it did not regain compliance with Nasdaq's Minimum Value of Listed Securities (MVLS) rule by the June 10, 2024 deadline, according to an SEC filing.
June 14, 2024 | 8:35 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Biora Therapeutics did not meet Nasdaq's MVLS compliance deadline, which could lead to potential delisting or other regulatory actions.
Failure to meet Nasdaq's MVLS compliance deadline typically results in negative market sentiment and potential delisting, which can significantly impact the stock price negatively.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100